SCHEMBL496324

SCHEMBL496324

O=C(Cl)c1ccc(C(F)(F)F)cc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.54
CES2 O00748 3/20 0.52
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 3/20 0.49
HPGD P15428 2/20 0.49
HSD17B10 Q99714 2/20 0.49
ALOX15 P16050 1/20 0.48
HTT P42858 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46
NTRK1 P04629 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CFTR P13569 1/20 0.44
PDE2A O00408 2/20 0.43
TMPRSS4 Q9NRS4 1/20 0.43
TRPV1 Q8NER1 1/20 0.43
GPR27 Q9NS67 1/20 0.43
USP2 O75604 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8674347 0.93 GAA (0.49) GAACES2ALDH1A1KDM4EHPGD
SCHEMBL17732182 0.86 KIF11 (0.54) GAACES2ALDH1A1ALOX15NTRK1
SCHEMBL15918189 0.85 ALDH1A1 (0.46) GAACES2ALDH1A1KDM4EHPGD
SCHEMBL7733997 0.85 CES2 (0.46) GAACES2ALDH1A1KDM4EHPGD
SCHEMBL283293 0.85 CES2 (0.52) GAACES2ALDH1A1KDM4EHPGD
SCHEMBL28188798 0.84 GAA (0.57) GAACES2ALDH1A1KDM4EHPGD
Fluoride SCHEMBL31028111 0.83 CES2 (0.50) GAACES2ALDH1A1KDM4EHPGD
SCHEMBL18130731 0.83 ALDH1A1 (0.47) GAACES2ALDH1A1HPGDHSD17B10
SCHEMBL283914 0.82 KDM4E (0.65) GAACES2ALDH1A1KDM4EHPGD
SCHEMBL3023134 0.82 CES2 (0.53) GAACES2ALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025043151-A2 BICYCLIC DGK INHIBITORS INCYTE CORPORATION (US) 2025-02-27 WO disclosed
US-20250066363-A1 Bicyclic DGK Inhibitors INCYTE CORPORATION 2025-02-27 US disclosed
EP-3459958-B1 PROCESS AND INTERMEDIATES FOR PREPARING PRODRUGS OF PYRIDONE AMIDES USEFUL AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMA (US) 2024-08-07 EP disclosed
CN-118271285-A Azetidine-containing amide derivative, preparation method and application thereof 贵州大学 2024-07-02 CN disclosed
CN-116874441-A Flexible aryl formamide derivative containing 1,2, 4-oxadiazole as well as preparation method and application thereof 贵州大学 2023-10-13 CN disclosed
US-11773119-B2 Prodrugs of pyridone amides useful as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-03 US disclosed
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-09-14 US disclosed
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-09-14 US disclosed
CN-111655678-B Apoptosis signal regulating kinase-1 inhibitor and application thereof 广州市恒诺康医药科技有限公司 2023-08-22 CN disclosed
CN-112955436-B 6-oxo-1, 6-dihydropyridazine derivatives, preparation method and application thereof in medicines 福建盛迪医药有限公司 2023-08-11 CN disclosed
WO-1998006402-A1 TREATMENT OF THE COMMON COLD OR ALLERGIC RHINITIS ELI LILLY AND COMPANY (US) 1998-02-19 WO disclosed
US-5646294-A FUNGICIDES J. URIACH & CIA. S.A. (ES) 1997-07-08 US disclosed
WO-1997013512-A1 N-[2-SUBSTITUTED-3-(2-AMINOETHYL)-1H-INDOL-5-YL]-AMIDES: NEW 5-HT1F AGONISTS ELI LILLY AND COMPANY (US) 1997-04-17 WO disclosed
EP-0768301-A1 N-(2-substituted-3-(2-aminoethyl)-1H-indol-5-yl)-amides as new 5-HT1F agonists ELI LILLY AND COMPANY (US) 1997-04-16 EP disclosed
US-5478826-A Fungicides for human, animal and plants J. URIACH & CIA. S.A. (ES) 1995-12-26 US disclosed
CN-1029962-C Triazole derivatives, their preparation and their use as fungicides SANKYO CO (JP) 1995-10-11 CN disclosed
EP-0617031-A1 Orally active azole derivates J. URIACH & CIA. S.A. (ES) 1994-09-28 EP disclosed
EP-0332387-B1 Triazole derivatives, their preparation and their use as fungicides SANKYO CO (JP) 1993-11-24 EP disclosed
CN-1036759-A Triazole derivative, its preparation method and its purposes as mycocide SANKYO CO (JP) 1989-11-01 CN disclosed
EP-0332387-A1 Triazole derivatives, their preparation and their use as fungicides Sankyo Company Limited (JP) 1989-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066363-A1 Bicyclic DGK Inhibitors DGKA, DGKG, DGKK GAA 964/4885CES2 2000/4885ALDH1A1 3643/4885
US-11773119-B2 Prodrugs of pyridone amides useful as modulators of sodium channels TRPV1, P2RY1, P2RX3 GAA 4346/4885CES2 1703/4885ALDH1A1 886/4885
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN2A, SCN10A GAA 2969/4885CES2 789/4885ALDH1A1 2665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.